Astrazeneca (AZN) Leases (2019 - 2026)

Astrazeneca has reported Leases over the past 8 years, most recently at $1.8 billion for Q1 2026.

For Q1 2026, Leases rose 22.64% year-over-year to $1.8 billion; the TTM value through Mar 2026 reached $1.8 billion, up 22.64%, while the annual FY2025 figure was $1.7 billion, 24.8% up from the prior year.
Leases for Q1 2026 was $1.8 billion at Astrazeneca, up from $1.7 billion in the prior quarter.
Over five years, Leases peaked at $1.8 billion in Q1 2026 and troughed at $875.0 million in Q3 2022.
A 5-year average of $1.2 billion and a median of $1.2 billion in 2024 define the central range for Leases.
On a YoY basis, Leases climbed as much as 82.95% in 2022 and fell as far as 7.7% in 2022.
Year by year, Leases stood at $942.0 million in 2022, then rose by 16.77% to $1.1 billion in 2023, then increased by 26.82% to $1.4 billion in 2024, then grew by 24.8% to $1.7 billion in 2025, then increased by 4.54% to $1.8 billion in 2026.
Business Quant data shows Leases for AZN at $1.8 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.7 billion in Q3 2025.

Peer Comparison